More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$4.11B
EPS
-0.83
P/E ratio
--
Price to sales
2.8
Dividend yield
--
Beta
2.528844
Previous close
$18.56
Today's open
$18.38
Day's range
$17.14 - $18.70
52 week range
$13.74 - $40.99
show more
CEO
Andrew Dudum
Employees
2442
Headquarters
San Francisco, CA
Exchange
New York Stock Exchange
Shares outstanding
234412422
Issue type
Common Stock
Consumer Staples
Consumer Products - Household & Personal
Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy
Hims & Hers Health said it will now offer five new peptides and longevity treatments compounded in the U.S. as part of the initial rollout of its Peptides+ platform. The telehealth company will now offer compounded formulations of sermorelin, glutathione, and NAD+, as well as vitamin B-12 and L-carnitine, none of which are approved by the FDA.
CNBC • 4 hours ago

Hims & Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers (NYSE: HIMS) today announced the launch of Peptides+, a new specialty built around clinically-guided protocols designed to target health at the cellular level. After a clinical visit with a licensed provider, eligible customers may be prescribed a personalized treatment plan including up to five treatments at launch: Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine, depending on their needs as determined by their provider. Access to BPC.
Business Wire • 4 hours ago

Hims & Hers Health Stock Crashes After Earnings: Is Now the Time to Buy?
Hims & Hers Health grew its revenue by 49% last quarter. The company incurred a loss, however, as its gross margins deteriorated.
The Motley Fool • Nov 16, 2026

Hims & Hers: Further Expanding Internationally
Hims & Hers Health is a Strong Buy: my $23.8 implied share price offers roughly 20% upside while targeting a 15% annual return. International expansion is the principal growth driver, with revenue guidance raised to at least $650 million in 2026 and $1 billion expected in 2027. HIMS faces near-term margin pressure and subscriber headwinds; Q3 gross margin fell to 57%, while subscribers declined by 103,000 sequentially.
Seeking Alpha • Nov 16, 2026

Why Is Hims Stock Crashing, and is it a Buying Opportunity?
Revenue is increasing, but so are its operating expenses.
The Motley Fool • Nov 14, 2026

Hims & Hers Stock Just Plummeted 17%. Is the Stock a Buy Ahead of a Peptide Push?
Hims & Hers stock is facing margin pressure as it increases sales of branded weight-loss drugs and expands internationally. The company has a big opportunity in the peptide market.
The Motley Fool • Nov 13, 2026

Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks Investment Research • Nov 13, 2026

HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs
Hims & Hers unites with Lilly to offer FDA-approved weight-loss drugs, Zepbound and Foundayo, expanding patient access and strengthening its obesity care platform.
Zacks Investment Research • Nov 13, 2026

Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
Even a nearly 9% rebound on Wednesday, Nov. 11, couldn't undo a punishing start to the week for Hims & Hers Health NYSE: HIMS. Shares had already plunged nearly 12% ahead of Monday evening's Q3 earnings report, and disappointing results—a double miss—sent the stock tumbling another 16.6% on Tuesday.
MarketBeat • Nov 12, 2026

Hims & Hers Week in Review: Q3 Miss, Weak Q4 Outlook, Huberman Joins Board
Hims & Hers Health Inc. (NYSE:HIMS) had a busy week that included third-quarter results that missed estimates, a new board member in Andrew Huberman and a round of analyst price target changes.
Benzinga • Nov 11, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Hims & Hers Health Inc. Class A commission-free¹. Build wealth for the long term using automated trading and transfers.